P 
2.51
+9.13%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Protara Therapeutics
From its filings with the US Securities and Exchange Commission
Protara Therapeutics is based in New York, New York. Its shares trade on Nasdaq under the ticker TARA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2014, it reported revenue of $2.9m.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Oct 2014
- Employees
- 46
- Website
- protaratx.com ↗
- Head office
- 345 PARK AVENUE SOUTH, NEW YORK, NY, 10010
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Luke BesharIndependent Chairman of the Board$192,098
- Mr. Jesse SheffermanPresident, Chief Executive Officer, Director, since 2020$1.8m
- Mr. Patrick FabbioChief Financial Officer$1.0m
- Dr. Jacqueline ZummoChief Scientific Operations Officer$1.2m
- Ms. Hannah FryController
- Mr. William ConklingChief Commercial Officer
- Dr. Leonardo NicacioChief Medical Officer
- Dr. Barry FlannellyIndependent Director$66,598
- Dr. Roger GarceauIndependent Director$91,598
- Dr. Jane HuangIndependent Director$85,598
- Dr. Richard LevyIndependent Director$112,473
- Mr. Gregory SargenIndependent Director$75,598
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 35
- Social
- 90
- Governance
- 46
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Protara Therapeutics Inc has a strong focus on developing innovative drugs, leveraging advanced technologies and scientific expertise. This gives the company a competitive edge in the rapidly evolving pharmaceutical industry.
- The company boasts a robust intellectual property portfolio, comprising patents, trademarks, and proprietary technologies. This provides a solid foundation for future growth, establishing barriers for potential competitors and enhancing the company's market position.
Weaknesses
- At present, Protara Therapeutics Inc has a limited number of products in its portfolio. This dependence on a small product range poses a risk in terms of revenue diversification and future growth potential.
- The company heavily relies on collaborations and partnerships with other entities. While such alliances may provide access to resources and expertise, they also introduce dependency on external parties, increasing the vulnerability to potential delays or conflicts in decision-making.
Opportunities
- Protara Therapeutics Inc has the opportunity to expand its presence beyond its current market. Venturing into global markets could unlock new revenue streams and increase the company's market share, especially in regions with unmet medical needs.
- The company has the chance to form strategic partnerships with established pharmaceutical companies or research institutions. Collaborative relationships can provide access to additional resources, expertise, and distribution networks, accelerating the development and commercialization of new drugs.
Threats
- Protara Therapeutics Inc operates in a highly competitive industry, with numerous companies vying for market share. The presence of existing well-established competitors and the potential entry of new players pose threats to the company's market position and profitability.
- Compliance with constantly evolving regulations and requirements within the pharmaceutical industry is a significant challenge. Protara Therapeutics Inc must navigate and adapt to regulatory changes, ensuring timely approvals and avoiding potential setbacks in drug development and commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.